Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Short term Debt (2016 - 2025)

Pediatrix Medical (MD) has disclosed Short term Debt for 13 consecutive years, with $26.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Short term Debt rose 30.47% to $26.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.8 million, a 30.47% increase, with the full-year FY2025 number at $26.8 million, up 30.47% from a year prior.
  • Short term Debt was $26.8 million for Q4 2025 at Pediatrix Medical, up from $25.3 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $26.8 million in Q4 2025 to a low of $2.5 million in Q4 2021.
  • A 5-year average of $17.4 million and a median of $15.7 million in 2023 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: surged 498.31% in 2022, then decreased 0.02% in 2023.
  • Pediatrix Medical's Short term Debt stood at $2.5 million in 2021, then soared by 498.31% to $14.9 million in 2022, then grew by 0.1% to $14.9 million in 2023, then surged by 37.77% to $20.5 million in 2024, then skyrocketed by 30.47% to $26.8 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Short term Debt are $26.8 million (Q4 2025), $25.3 million (Q3 2025), and $23.7 million (Q2 2025).